DBL METHOTREXATE INJECTION BP 50mg/2ml (WITHOUT PRESERVATIVE)
Source of information: Drugbank (External Link). Last updated on: 3rd July 18
*Trade Name used in the content below may not be the same as the HSA-registered product.
Active Ingredient / Synonyms
4-amino-10-methylfolic acid | 4-amino-N(10)-methylpteroylglutamic acid | Amethopterin | Methotrexat | Méthotrexate | Methotrexatum | Metotrexato | MTX | N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid | Methotrexate |
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of tetrahydrofolate dehydrogenase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe, active rheumatoid arthritis (ACR criteria), or children with active polyarticular-course juvenile rheumatoid arthritis.
Mechanism of Action
Methotrexate anti-tumor activity is a result of the inhibition of folic acid reductase, leading to inhibition of DNA synthesis and inhibition of cellular replication. The mechanism involved in its activity against rheumatoid arthritis is not known.
Methotrexate is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Methotrexate inhibits folic acid reductase which is responsible for the conversion of folic acid to tetrahydrofolic acid. At two stages in the biosynthesis of purines and at one stage in the synthesis of pyrimidines, one-carbon transfer reactions occur which require specific coenzymes synthesized in the cell from tetrahydrofolic acid. Tetrahydrofolic acid itself is synthesized in the cell from folic acid with the help of an enzyme, folic acid reductase. Methotrexate looks a lot like folic acid to the enzyme, so it binds to it quite strongly and inhibits the enzyme. Thus, DNA synthesis cannot proceed because the coenzymes needed for one-carbon transfer reactions are not produced from tetrahydrofolic acid because there is no tetrahydrofolic acid. Methotrexate selectively affects the most rapidly dividing cells (neoplastic and psoriatic cells). Methotrexate is also indicated in the management of severe, active, classical, or definite rheumatoid arthritis.
Oral absorption is dose dependent in adults and leukemic pediatric patients. In adults, peak serum levels are reached within one to two hours. At doses of 30 mg/m^2 or less, methotrexate is generally well absorbed with a mean bioavailability of 60%. At doses greater than 80 mg/m^2, the absorption of the doses is significantly less due to a saturation effect.
* 0.18 L/kg [initial volume of distribution (Vd)] * 0.4 - 0.8 L/kg [steady state Vd] Methotrexate competes with reduced folates for active transport across cell membranes by means of a single carrier-mediated active transport process. At serum concentrations greater than 100 micromolar, passive diffusion becomes a major pathway by which effective intracellular concentrations can be achieved. Methotrexate does not cross the blood-brain-barrier.
Methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms which can be converted back to methotrexate by hydroxylase enzymes. These polyglutamates act as inhibitors of dihydrofolate reductase and thymidylate synthetase. A small amount of metabolism to 7-hydroxymethotrexate may occur at doses commonly prescribed. Furthermore, intestinal flora partially metabolizes methotrexate after oral administration.
Renal excretion is the primary route of elimination and is dependent upon dosage and route of administration. IV administration, 80% to 90% of the administered dose is excreted unchanged in the urine within 24 hours. There is limited biliary excretion amounting to 10% or less of the administered dose.
Low doses (less than 30 mg/m^2): 3 to 10 hours; High doses: 8 to 15 hours.
Methotrexate clearance rates vary widely and are generally decreased at higher doses. Delayed drug clearance has been identified as one of the major factors responsible for methotrexate toxicity.
Symptoms of overdose include bone marrow suppression and gastrointestinal toxicity. LD50=43mg/kg(orally in rat).
Although best effort has been made to ensure the information provided is correct and updated, users are advised to visit HSA Official website whenever in doubt. Please see Disclaimers.
We welcome all the content error reporting/feedback. Please contact us @ Text Us!
DBL METHOTREXATE INJECTION BP 50mg/2ml (WITHOUT PRESERVATIVE) was registered with Health Science Authority of Singapore by HOSPIRA SINGAPORE PTE LTD. It is marketed with the registration number of SIN00758P with effective from 1988-04-05.
This product contains 50mg/2ml of Methotrexate in the form of INJECTION.
The medicine was manufactured by Hospira Australia Pty Ltd in AUSTRALIA
It is a Presciption Only Medicine which can only be obtained from a doctor or a dentist, or from a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Anatomical Therapeutic Chemical (ATC) Classification
Products Containing as Single Ingredient
|Drug ID||Trade Name||Active Ingredients||Forensic Class||Registrant||Status|
|1||DEXTROMETHORPHAN LINCTUS 15mg/5ml||Dextromethorphan||P Only||DRUG HOUSES OF AUSTRALIA PTE LTD||Active|
|22||ZENMOLIN SYRUP 2mg/5ml||Salbutamol||P Only||DRUG HOUSES OF AUSTRALIA PTE LTD||Active|
|41||APO-PROPRANOLOL TABLET 40mg||Propranolol||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|42||APO-DIAZEPAM TABLET 2mg||Diazepam||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|44||APO-DIAZEPAM TABLET 5mg||Diazepam||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|45||APO-DIAZEPAM TABLET 10mg||Diazepam||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|46||APO-PROPRANOLOL TABLET 10mg||Propranolol||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|55||APO-ISDN TABLET 10mg||Isosorbide Dinitrate||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|63||DIAPO TABLET 10mg||Diazepam||POM||BEACONS PHARMACEUTICALS PTE LTD||Active|
|64||FURMIDE TABLET 40mg||Furosemide||POM||BEACONS PHARMACEUTICALS PTE LTD||Active|
Products Containing as Mixture Ingredient
|Drug ID||Trade Name||Active Ingredients||Forensic Class||Registrant||Status|
|4||DIPHENHYDRAMINE EXPECTORANT||Ammonium Chloride|Diphenhydramine|Sodium Citrate||P Only||DRUG HOUSES OF AUSTRALIA PTE LTD||Active|
|5||DIPHENHYDRAMINE EXPECTORANT PAED.||Ammonium Chloride|Diphenhydramine|Sodium Citrate||P Only||DRUG HOUSES OF AUSTRALIA PTE LTD||Active|
|400||FAKTU SUPPOSITORY||Cinchocaine|Policresulen||P Only||TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE LTD||Active|
|407||TRIMAXAZOLE TABLET||Sulfamethoxazole|Trimethoprim||POM||BEACONS PHARMACEUTICALS PTE LTD||Active|
|435||APO-SULFATRIM TABLET||Sulfamethoxazole|Trimethoprim||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|508||APO-SULFATRIM PEDIATRIC TABLET||Sulfamethoxazole|Trimethoprim||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|526||B.S. SUSPENSION||Sulfamethoxazole|Trimethoprim||POM||APEX PHARMA MARKETING PTE LTD||Active|
|583||CO-TRIMEXAZOLE SUSPENSION||Sulfamethoxazole|Trimethoprim||POM||BEACONS PHARMACEUTICALS PTE LTD||Active|
|676||BANEOCIN OINTMENT||Bacitracin|Neomycin||POM||NOVARTIS (SINGAPORE) PTE LTD||Active|
|678||BANEOCIN POWDER||Bacitracin|Neomycin||POM||NOVARTIS (SINGAPORE) PTE LTD||Active|